• Ross Drake, Grace Prael, Yinyin Phyo, Sungwon Chang, Jane Hunt, Anthony Herbert, Christine Mott, Jenny Hynson, Marianne Phillips, Mary Cossich, Martha Mherekumombe, Min Sun Kim, Poh Heng Chong, Maja Abitz, Mercedes Bernada, Madeline Avery, Matt Doogue, Debra Rowett, and David Currow.
• Starship Children's Health (R.D.), Auckland, New Zealand; University of Technology Sydney (UTS) (R.D., G.P., Y.P., S.C., J.H., A.H., D.C.), Centre for Improving Palliative, Aged, and Chronic Care through Clinical Research and Translation (IMPACCT), Sydney, Australia. Electronic address: RossD@adhb.govt.nz.
• J Pain Symptom Manage. 2024 Mar 1; 67 (3): 212222.e1212-222.e1.

ObjectiveGabapentin is commonly used to treat pain in children receiving pediatric palliative care. This study describes the real-world use of gabapentin and the associated benefits and adverse effects/events (AEs).MethodsA prospective, multicenter cohort of standardized data collection after a clinical decision was made to use gabapentin for managing neuropathic or nociplastic pain in children attended on by a pediatric palliative care service. It was conducted across 11 sites in seven countries including hospital, inpatient, and outpatient services. Clinical outcomes were graded using pain scales validated for age and cognitive ability and the National Cancer Institute Common Terminology Criteria for Adverse Events (NCICTCAE) at baseline, 14 days, 28 days, six weeks and 12 weeks after initiation of gabapentin. Ad-hoc safety reporting continued throughout the study.ResultsData were collected from 127 children with a median age of 4.7 years (IQR 0.1-17.9); 61% had a neurological disorder, 21% advanced cancer and the cohort had a high level of disability (Lansky/Karnofsky performance score 37.1). Gabapentin was prescribed at standard pediatric doses. On average, 76% of children had a reduction in pain and 42% experienced a potential AE. The mean pain score decreased from 6.0 (SD 2.6) at baseline to 3.3 (SD 2.4) at 14 days and 1.8 (SD 1.8) after 12-weeks of gabapentin therapy. Ten percent had increased pain at each time point. AEs did not increase when individual changes over time were accounted for except for somnolence (7%). Serious AEs attributable to gabapentin were possible or probable in 3% of children.ConclusionsGabapentin prescribed at standard doses for advanced cancer and severe neurological injury in children under a pediatric palliative care service was associated with generally improved pain intensity at previously described levels of adverse effects.Crown Copyright © 2023. Published by Elsevier Inc. All rights reserved.

25 keywords...

hide…